← FDA DRUG APPROVALS

FDA ANDA · ANDA200222

LINEZOLID

Sponsor: TEVA PHARMS

APPLICATION
ANDA200222
TYPE
ANDA
ORIGINAL APPROVAL
2012-06-27
LATEST ACTION
2024-11-04
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

LINEZOLIDDiscontinued
LINEZOLID 600MG/300ML (2MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2024-11-04Labeling · Supplement 6 · standardAP
2024-11-04Labeling · Supplement 5 · standardAP
2019-06-26Labeling · Supplement 4 · standardAP
2016-01-05Labeling · Supplement 3 · standardAP
2016-01-05Labeling · Supplement 1 · standardAP
2012-06-27Not Applicable · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →